SCHEMBL2808656

SCHEMBL2808656

COCCCOc1cc(OCc2ccccc2)cc(C(=O)OC)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
HPGD P15428 1/20 0.59
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
KDM4E B2RXH2 2/20 0.57
NPC1 O15118 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.52
SMPD1 P17405 1/20 0.51
MAOB P27338 2/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
GCK P35557 1/20 0.49
NR4A2 P43354 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.47
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9323928 0.93 LMNA (0.60) LMNAHPGDMEN1KMT2AKDM4E
SCHEMBL391547 0.90 MEN1 (0.71) LMNAHPGDMEN1KMT2ANPC1
SCHEMBL3488958 0.89 MEN1 (0.75) LMNAMEN1KMT2AKDM4ENPC1
SCHEMBL2650902 0.88 LMNA (0.60) LMNAHPGDMEN1KMT2ANPC1
SCHEMBL183994 0.87 LMNA (0.70) LMNAHPGDMEN1KMT2ANPC1
SCHEMBL31007012 0.87 PLA2G2A (0.58) LMNAHPGDMEN1KMT2AKDM4E
SCHEMBL9324726 0.87 LMNA (0.60) LMNAHPGDMEN1KMT2AKDM4E
SCHEMBL9167382 0.87 PLA2G2A (0.58) LMNAHPGDMEN1KMT2AKDM4E
SCHEMBL3488635 0.87 MEN1 (0.58) LMNAMEN1KMT2AKDM4ENPC1
SCHEMBL9323897 0.87 PLA2G2A (0.54) LMNAHPGDMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
CN-101679324-A Morpholine derivatives MITSUBISHI TANABE PHARMA CORP 2010-03-24 CN disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 LMNA 1966/4885HPGD 1835/4885MEN1 167/4885
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 LMNA 2412/4885HPGD 1367/4885MEN1 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.